Market

    What will be the annual revenue of lecanemab-irmb in 2025?

    2
    Resolution / Starting Odds

    Less than $500 million25%

    $500 million to $1 billion25%

    $1 billion to $2 billion25%

    More than $2 billion25%

    Eisai and Biogen financial reports

    Story

    FDA Approves January 26, 2025, Monthly Maintenance Dosing for Eisai/Biogen's lecanemab-irmb in Early Alzheimer's Treatment

    FDA Approves January 26, 2025, Monthly Maintenance Dosing for Eisai/Biogen's lecanemab-irmb in Early Alzheimer's Treatment

    Jan 27, 2025, 02:46 AM

    The U.S. Food and Drug Administration (FDA) has approved monthly maintenance dosing of LEQEMBI® (lecanemab-irmb) for the treatment of early Alzheimer's disease. This decision, announced on January 26, 2025, allows for intravenous administration of the drug developed by Eisai Co. Ltd. and Biogen. The approval signals a significant advancement in the treatment options available for early-stage Alzheimer's patients, providing a new avenue for ongoing management of the disease.

    View original story

    Similar markets

    More than $2 billion25%

    Less than $500 million25%

    $500 million to $1 billion25%

    $1 billion to $2 billion25%

    $1 billion to $1.5 billion25%

    Less than $1 billion25%

    Exceeds $2 billion25%

    $1.5 billion to $2 billion25%

    $1 billion to $2 billion25%

    $2 billion to $3 billion25%

    More than $3 billion25%

    Less than $1 billion25%

    Other25%

    No clear leader25%

    Eli Lilly25%

    Eisai/Biogen25%

    Less than 10%25%

    More than 30%25%

    21% to 30%25%

    10% to 20%25%